COA questions Dengvaxia procurement process

Lian Buan
COA questions Dengvaxia procurement process


The Commission on Audit also notes a discrepancy on the shelf life of the vaccine in the procurement documents

MANILA, Philippines – The Commission on Audit (COA) flagged several aspects in the government’s procurement of anti-dengue vaccine Dengvaxia, including holding pre-procurement activities even before the memorandum agreement was (MOA) signed.

In the COA’s 2017 audit report of the Philippine Children’s Medical Center (PCMC), state auditors noted that 6 pre-procurement activities were conducted by the hospital from January to February 2016, before the agreement with the  Department of Health (DOH) was signed on February 19, 2016.

PCMC was the procuring entity for Dengvaxia during the term of former health secretary Janette Garin. The draft report  of Senator Richard Gordon, who led the Senate inquiry into the Dengvaxia issue, recommended draft charges against PCMC Executive Dirtector Julius Lecciones, Garin, and former president Benigno Aquino III. (READ: Aquino ‘ready’ to face more complaints amid Gordon Dengvaxia report)

The PCMC conducted a pre-procurement conference, posting of invitation to bid, pre-bid conference, bid opening, bid evaluation, and post qualification before it signed the MOA with DOH to buy P3 billion worth of anti-dengue vaccines.

DENGVAXIA. The table above shows the pre-procurement activites of the Philippine Children's Medical Center for the dengue vaccine Dengvaxia, held before the agreement to buy was supposedly signed on February 19, 2016. Photo from COA report

In its response to COA, the PCMC disputed the finding.

“It is not true that bidding was conducted before the effectivity of the MOA between the DOH and PCMC,” it said.

PCMC said February 19 was only the notarization date, and the agreement had in fact taken into effect before the pre-procurement conference.

“The DOH Legal Service had reviewed the MOA as early as January 14, 2016, and posed no objection thereto and during the Board of Trustees Meeting, the Board authorized PCMC to implement the dengue vaccination program and accept the corresponding amount from the DOH,” the PCMC said as cited in the audit report. (READ: TIMELINE: Dengue immunization program for public school students)

The COA told the PCMC to “strictly comply with the requirements under the Revised IRR of RA 9184 on the procurement of goods and services.”

Aquino had defended the apparent rush in procurement, citing limits in the budget process that pushed his administration to make use of legal remedies and make sure the vaccines were bought in the early part of 2016, and protect children from dengue as early as possible. 

Formulary exemption

All drugs that shall be bought by the government should be in the NatIonal Formulary. Dengvaxia was not in the formulary, but it had previously secured a one-year provisional exemption from the Formulary Executive Council (FEC).

This was the go-signal to buy Dengvaxia, but COA questioned the process.

“Review of the documents submitted showed that the FEC recommendation for provisional exemption from the Philippine National Drug Formulary (PNDF) was not submitted to the National Center for Pharmaceutical Access and Management (NCPAM) Program Director as required under DOH A.O. No. 2012-0023 but to the DOH Secretary,” COA said.

The PCMC said the DOH Secretary exercises superivision over the NCPAM, and that the secretary’s approval is sanctioned under an earlier department order. The PCMC said, however, that it cannot be made answerable for the secretary’s actions, referring to Garin.

The shelf life of the vaccine was also mentioned in the COA report, after state auditors observed that while the contract said shelf life is 18 to 24 months, the purchase order stated only 12 months. The PCMC said the mistake in the purchase order was a “mere inadvertence” and the shelf life is indeed 18 to 24 months, pursuant to the contract.

These issues had already been threshed out in congressional hearings, and complaints had been filed against Aquino, Garin, et al.

Vaccine supplier Sanofi Pasteur has agreed to refund P1.4 billion of unused vaccines, in light of controversies surrounding Dengvaxia.

The DOH has also already stopped the dengue vaccination program. The COA acknowledges that at this point, their recommendations are already moot.

“We agree that the implementation of the audit recommendations for the purchase of the dengue vaccines have become moot and academic. The inclusion in this Annual Audit Report of the said audit observations is to ensure that implementation of future projects/programs/transactions of similar nature be dealt with proper caution and the due observance of laws/rules/regulations governing the transactions,” the COA said. –

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.


Lian Buan

Lian Buan covers justice and corruption for Rappler. She is interested in decisions, pleadings, audits, contracts, and other documents that establish a trail. If you have leads, email or tweet @lianbuan.